POLISCOPE
Back to bills

The civic record

Read. Follow. Verify.
High Impact

Pennsylvania requires health insurers to cover FDA-approved treatments and tests for Alzheimer's disease by 2028

Original title: An Act amending the act of May 17, 1921 (P.L.682, No.284), known as The Insurance Company Law of 1921, in casualty insurance, providing for coverage for treatments to slow the progression of Alzheimer's disease and related dementias.

Last action · August 18, 2026: Referred to INSURANCE, Aug. 18, 2026Sponsors: Kyle Mullins and 40 others

Introduced
Committee
Floor Vote
Passed
Law

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Public stanceCommunity reactions are separate from the official record and reporting.

What This Bill Would Do

Beginning January 1, 2028, health insurers in Pennsylvania must provide coverage for all medically necessary diagnostic testing, treatments, and FDA-approved medications prescribed to slow the progression of Alzheimer's disease and related dementias, without requiring .

Why it matters

Patients with Alzheimer's disease and related dementias will gain guaranteed insurance coverage for specialized progression-slowdown treatments and tests without needing to try alternative therapies first, impacting how health plans structure their coverage and formularies.

Who It Would Affect

Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.

Directly affected

health insurance policyholders in Pennsylvania

Policyholders diagnosed with Alzheimer's disease or related dementias gain guaranteed access to insurance coverage for diagnostic testing and FDA-approved progression-slowdown treatments without step therapy.

Directly affected

insurers offering health insurance policies in Pennsylvania

Insurers must update their health insurance policies and coverage terms by January 1, 2028, to include prescribed diagnostic testing and FDA-approved treatments for Alzheimer's without step therapy.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

When does the health insurance coverage requirement for Alzheimer's treatments go into effect?
Insurers must provide this coverage no later than January 1, 2028, and the overall act takes effect in 60 days.
Does this requirement apply to Medicare supplement or long-term care policies?
No, the legislation explicitly excludes Medicare supplement policies, long-term care policies, accident-only policies, and several other limited-benefit policy types.
Can insurers require patients to try other drugs first before approving coverage for Alzheimer's medications?
No, coverage under this section shall not include .

What else do you want to know?

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Where This Stands

Currently in committee. The next step in the legislative lifecycle is Floor Vote.

Procedural history

1 action
  1. Aug 18, 2026HouseCommittee
    Referred to INSURANCE, Aug. 18, 2026

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

Lobbying Activity

No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Sponsors

Show 36 more sponsors

Connected Entities

State Workmen's Insurance Fund, United States Food and Drug Administration
OrganizationState Workmen's Insurance Fund“Mentioned in the title of the Insurance Company Law of 1921”Map →
OrganizationUnited States Food and Drug Administration“Approves medications prescribed to slow the progression of Alzheimer's disease”Map →

Sources

Open source document

www.palegis.us

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy40
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz35
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record